|  |
| --- |
| CASE 1 |
|  |
| Tumor Description | **Grade** | **Tumor Size** |
| Primary Site |  | **Clinical** |  | **Clinical** |  |
| Laterality |  | **Pathological** |  | **Pathological** |  |
| Histology |  | **Post Therapy (yc)**  |  | **Summary** |  |
| Behavior |  | **Post Therapy (yp)**  |  |   |
| AJCC Staging Items |
| Clinical T  |  | **Pathological T** |  | **Post-therapy cT** |   | **Post-therapy pT** |   |
| cT Suffix  |  | **pT Suffix** |  | **ypT Suffix** |   | **ypT Suffix** |   |
| Clinical N  |  | **Pathological N** |  | **Post-therapy cN** |   | **Post-therapy pN** |   |
| cN Suffix  |  | **pN Suffix** |  | **ypN Suffix** |   | **ypN Suffix** |   |
| Clinical M  |  | **Pathological M** |  | **Post-therapy M** |   | **Post-therapy M** |   |
| Stage Group  |  | **Stage Group** |  | **Stage Group** |   | **Stage Group** |   |
| SS2018/EOD |
| Summary Stage 2018  |  |   |
| Extent of Disease |
| EOD Primary Tumor |  | **EOD Regional Nodes** |  | **EOD Mets** |  |

|  |  |
| --- | --- |
| Regional Nodes Positive |  |
| Regional Nodes Examined |  |
| SSDI | **LN H/N VI-VII** |  | **LN H/N Other** |  |
| Schema Discriminator 1 |  | **ENE Pathological** |  | **LN H/N levels I-III** |  |
| ENE Clinical |  | **LN Size of Mets** |  | **LN H/N levels IV-V** |  |
| Treatment |
| Surgery Codes | **Systemic Therapy Codes** |
| Diagnostic Staging Procedure |  | **Chemotherapy** |  |
| Surgical Procedure of Primary Site |  | **Hormone Therapy** |  |
| Scope of RLN Node Surgery |  | **Immunotherapy** |  |
| Radiation |
| Phase | 1 2 3 |  | 1 2 3 |
| Primary Treatment Volume |  | **Dose Per fraction** |  |
| Draining LN  |  | **Fractions** |  |
| Modality |  | **Total Dose** |  |
| EB Planning Technique |  |  |  |

|  |
| --- |
| CASE 2 |
| Tumor Description | **Grade** | **Tumor Size** |
| Primary Site |  | **Clinical** |  | **Clinical** |  |
| Laterality |  | **Pathological** |  | **Pathological** |  |
| Histology |  | **Post Therapy (yc)**  |  | **Summary** |  |
| Behavior |  | **Post Therapy (yp)**  |  |   |
| AJCC Staging Items |
| Clinical T  |  | **Pathological T** |  | **Post-therapy cT** |   | **Post-therapy pT** |   |
| cT Suffix  |  | **pT Suffix** |  | **ypT Suffix** |   | **ypT Suffix** |   |
| Clinical N  |  | **Pathological N** |  | **Post-therapy cN** |   | **Post-therapy pN** |   |
| cN Suffix  |  | **pN Suffix** |  | **ypN Suffix** |   | **ypN Suffix** |   |
| Clinical M  |  | **Pathological M** |  | **Post-therapy M** |   | **Post-therapy M** |   |
| Stage Group  |  | **Stage Group** |  | **Stage Group** |   | **Stage Group** |   |
| SS2018/EOD |
| Summary Stage 2018  |  |   |
| Extent of Disease |
| EOD Primary Tumor |  | **EOD Regional Nodes** |  | **EOD Mets** |  |

|  |  |
| --- | --- |
| Regional Nodes Positive |  |
| Regional Nodes Examined |  |
| SSDIs |
| Schema Discriminator 2 |  | **ENE Pathological** |  |
| ENE Clinical |  | **LN Size of Mets** |  |
| Treatment |
| Surgery Codes | **Systemic Therapy Codes** |
| Diagnostic Staging Procedure |  | **Chemotherapy** |  |
| Surgical Procedure of Primary Site |  | **Hormone Therapy** |  |
| Scope of Regional Lymph Node Surgery |  | **Immunotherapy** |  |
| Radiation |
| Phase | 1 2 3 |  | 1 2 3 |
| Primary Treatment Volume |  | **Dose per FX** |  |
| Draining LN |  | **Fractions** |  |
| Modality  |  | **Total Dose** |  |
| EB Planning technique |  |  |  |

|  |
| --- |
| CASE 3 |
| Tumor Description | **Grade** | **Tumor Size** |
| Primary Site |  | **Clinical** |  | **Clinical** |  |
| Laterality |  | **Pathological** |  | **Pathological** |  |
| Histology |  | **Post Therapy (yc)**  |  | **Summary** |  |
| Behavior |  | **Post Therapy (yp)**  |  |   |
| AJCC Staging Items |
| Clinical T  |  | **Pathological T** |  | **Post-therapy cT** |   | **Post-therapy pT** |   |
| cT Suffix  |  | **pT Suffix** |  | **ypT Suffix** |   | **ypT Suffix** |   |
| Clinical N  |  | **Pathological N** |  | **Post-therapy cN** |   | **Post-therapy pN** |   |
| cN Suffix  |  | **pN Suffix** |  | **ypN Suffix** |   | **ypN Suffix** |   |
| Clinical M  |  | **Pathological M** |  | **Post-therapy M** |   | **Post-therapy M** |   |
| Stage Group  |  | **Stage Group** |  | **Stage Group** |   | **Stage Group** |   |
| SS2018/EOD |
| Summary Stage 2018  |  |   |
| Extent of Disease |
| EOD Primary Tumor |  | **EOD Regional Nodes** |  | **EOD Mets** |  |

|  |  |
| --- | --- |
| Regional Nodes Positive |  |
| Regional Nodes Examined |  |
| SSDIs |
| Schema Discriminator 2 |  | **ENE Pathological** |  |
| ENE Clinical |  | **LN Size of Mets** |  |
| Treatment |
| Surgery Codes | **Systemic Therapy Codes** |
| Diagnostic Staging Procedure |  | **Chemotherapy** |  |
| Surgical Procedure of Primary Site |  | **Hormone Therapy** |  |
| Scope of Regional Lymph Node Surgery |  | **Immunotherapy** |  |
| Radiation |
| Phase | 1 2 3 |  | 1 2 3 |
| Primary Treatment Volume |  | **Dose per FX** |  |
| Draining LN |  | **Fractions** |  |
| Modality  |  | **Total Dose** |  |
| EB Planning technique |  |  |  |